HAMLET (Human Alpha-Lactalbumin Made Lethal to Tumor Cells) - A Hope for the Cancer Patients

Salauddin Al Azad* and Md. Iqbal Khan

Biotechnology and Genetic Engineering Discipline, Life Science School, Khulna University, Bangladesh

*Corresponding author: Salauddin Al Azad, Biotechnology and Genetic Engineering Discipline, Life Science School, Khulna University, Khulna, Bangladesh, Email: abdullahsyum1992@gmail.com

Abstract

Cancer is a malignant disease which is in most part incurable. It is not curable through normal medication. Different cure techniques have already equipped to wipe cancer out but still a mess that cancer finds its own way-out. Oncolytic viral therapy is a new promising strategy against cancer. Oncolytic viruses (OVs) can replicate in cancer cells but not in normal cells, leading to lysis of the tumor mass but are recognized by the immune system as pathogens and the consequent antiviral response could represent a big hurdle for OVs makes the concept compromised for cancer treatment or malignant metastasis. Every human cell has a hereditary program that upon enactment will cause cell demise, named apoptosis. Cancer cells can develop because of imbalanced expansion, cell cycle guideline and their apoptosis hardware: genomic mutant particles bringing about non-practical professional apoptotic proteins or over-articulation of against apoptotic sister proteins which structure the premise of tumor development. Shockingly, exercises gained from infections demonstrate that malignancy can’t be viewed essentially as the inverse of apoptosis. Using anticancer genes as a therapy for cancer can be effective as they can go through the gene lines and make a call for destruction of malignancy. HAMLET (Human Alpha-lactalbumin Made Lethal to Tumor Cells) is such an anticancer gene which is found in human milk that can be effective in cancer treatment and also refusing new path making of cancer.

Keywords: HAMLET; Oncolytic Viruses; Apoptosis; P53; HDI; MAPK

Abbreviations: Hamlet: Human Alpha-Lactalbumin Made Deadly to Tumor Cells; MAL: Multimeric Alpha-Lactalbumin; OV: Oncolytic Viruses; Bcl2: B-Cell Lymphoma 2; HDI: Histone Deacetylase Inhibitor; P21waf1: Cyclin-Dependent Kinase Inhibitor 1; MAPK: Mitogen Activated Protein Kinase; Gtpase: Guanosin Tri Phospatease; P53: Phosphoprotein 53.

Introduction

Anticancer genes are proto-oncogenes when become oncogenic ectopically overexpressing, explicitly annihilate tumor cells without hurting typical cells [1]. This phone obliteration emerges for an assortment of systems, for example, apoptosis, mitotic disaster pursued by apoptosis or corruption, and autophagy.
Anticancer qualities rose up out of concentrates on disease cells in the late 1990s. Viruses were found over a century back however from early occasional ailments like disease and particularly leukemia was endeavored to be treated with infections. All through the written history of illnesses, there have been perceptions of malignant growth relapse upon characteristic co-disease with infections [2]. HAMLET is a conceivable chemotherapeutic operator with the capacity to kill malignant growth cells. Alpha-lactalbumin is the essential protein part of human milk. In a recent report, it has revealed that multimeric alpha-lactalbumin (MAL), a compound confined from a small amount of human milk called casein, incited what gave off an impression of being apoptosis in human lung carcinoma cells, pneumococcus and different pathogens, while leaving solid, separated cells [2]. It has been the ideal fix in this case. The dynamic segment in charge of the tumoricidal movement was observed to be a complex of alpha-lactalbumin and oleic acid. Its activity is the opposite of the oncogens. HAMLET (Human Alpha-lactalbumin Made Lethal to Tumor Cells) is a sub-atomic complex got from human milk that kills tumor cells by a procedure taking after apoptosis. The intricate comprises of mostly unfurled Alpha-lactalbumin and oleic corrosive, and both the protein with the unsaturated fat are required for cell demise. HAMLET has expansive antitumor activity in vitro, and its restorative impact has been affirmed in vivo in a human glioblastoma rodent xenograft demonstration in patients with skin papillomas and in patients with bladder malignancy. The instruments of tumor-cell passing stay hazed, be that as it may.

Following the experience with tumor cells, HAMLET attacks the cells what’s more, causes mitochondrial layer depolarization, cytochrome c discharge, phosphatidylserine presentation, and a low caspase reaction. A small amount of the cells experiences morphological changes normal for apoptosis, yet caspase restraint does not protect the cells and Bcl-2 overexpression or modified p53 status does not impact on the affectability of tumor cells to HAMLET. HAMLET additionally makes a condition of unfurled protein over-burden and enacts 20S proteasomes, which adds to cell demise. In parallel, HAMLET translocates to tumor cell cores, where high-fondness collaborations with histones cause chromatin interruption, loss of translation, and atomic buildup. The diminishing cells moreover show morphological changes perfect with macro-autophagy and later ponders demonstrate that macro-autophagy is associated with the cell passing reaction to HAMLET. The outcomes propose that HAMLET which is similar to a hydra with numerous heads, may connect with a few significant cell organelles, in this way actuating a few types of cell demise, in parallel. This multifaced nature may underlie the quick passing reaction of tumor cells and the expansive antitumor action of HAMLET.

Figure 1: HAMLET is defined as the product of partially unfolded Alpha-lactalbumin and oleic acid.

Through programmed cell death the human body dispenses with undesirable cells without bringing out an inflammatory reaction [3,4]. Cells experiencing customized cell death notifying an unmistakable morphological appearance described by cell shrinkage, membrane blistering, atomic buildup, and fragmentation with the arrangement of ‘apoptotic bodies’; this sort of cell passing is for the most part referred to as apoptosis [3,4]. HAMLET alters the structure of chromatin and trigger tumor cell demise. HDIs trigger tumor cell demise by reestablishing the outflow of antitumor qualities, though HAMLET ties histones with high fondness and changes the chromatin structure. This ponder thought about the impacts of HAMLET on tumor cell feasibility, histone acetylation, and DNA trustworthiness when the antagonists were joined. HDI pretreatment caused a stamped increment in the demise reaction to HAMLET and HAMLET a further increment in the histone
hyperacetylation reaction to HDIs. Cell demise was joined by expanded DNA harm and diminished p21WAF1 articulation when the two agonists were consolidated. We recommend that the cooperative energy depends on various however uniting demise pathways, which include modifications of the chromatin. As HDIs and HAMLET have archived remedial impacts, the joined utilization of HAMLET and HDIs may be of an incentive in the treatment of malignant growth. Tumor cell passing expanded particularly when HDIs and HAMLET were joined and the impact was synergistic when TSA was included prior to HAMLET. The sub-atomic premise of this cooperative energy is misty, yet a few passing pathways might be talked about. Caspases are basic for the execution of apoptosis and HDIs have been proposed to trigger cell passing by means of the extraneous, demise receptor–subordinate pathway and by means of the inborn mitochondrial demise pathway through actuation or hindrance of explicit Bcl-2 relatives, by means of the direction of responsive oxygen species and through cell cycle [5]. HAMLET acts straightforwardly on the mitochondria furthermore, triggers an effector caspase reaction and the atomic caspase 2 reaction to HAMLET may add to assist mitochondrial enactment. The demise of HAMLET-treated cells is caspase independent, in any case [6,7]. In the present examination, the DNA harm reaction was appeared to be caspase-free. supporting the idea that traditional apoptosis isn't the way to the joined impact of HAMLET and TSA.

<table>
<thead>
<tr>
<th>Reaction mode</th>
<th>Activity</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Apoptosis mimic mode of action provoked by HAMLET</td>
<td>The potentiality of HAMLET based treatment of human glioblastoma cells in brain xenograft through mechanisms mimic to apoptosis have proved clinically in recent years</td>
<td>[8]</td>
</tr>
<tr>
<td>B. Simultaneous anticancer and antibacterial activity of HAMLET</td>
<td>Investigation for proteins with blocking properties of adhesion of bacteria to cancer cells have already commenced and instead one of the milk proteins exposed with actual killing power of cancer cells while leaving the normal cells unharmed</td>
<td>[9]</td>
</tr>
<tr>
<td>C. HAMLET has been shown to target skin papillomas and bladder cancers</td>
<td>The apoptotic response that accompanies death in HAMLET treated tumor cells and the role of mitochondria in this process have analyzed through progressive inhibition of MAPK kinases and GTPases</td>
<td></td>
</tr>
<tr>
<td>D. HAMLET act as molecular signal modulator to the APC mutated cells in cancer accumulating in tumour tissue precisely and reducing β-catenin and related tumour markers</td>
<td>HAMLET proved itself as hyperactive antagonist to colon cancer with APC mutation in individuals as a new, peroral agent</td>
<td></td>
</tr>
<tr>
<td>E. Tumoricidal HAMLET complex can identify conserved death pathways suitable for targeting</td>
<td>Alpha-lactalbumin is a substrate specifier in lactose synthase complex, showing its antitumor activity after partial unfolding and binding to oleic acid molecule. This configuration unifies HAMLET as therapeutic molecular complex</td>
<td>[10]</td>
</tr>
<tr>
<td>F. Plasma membrane disruption of protein-lipid complex</td>
<td>HAMLET is a complex of Alpha-lactalbumin and oleic acid which is also termed as liprotide, have positive starring in cancer cell membrane disposal</td>
<td>[11]</td>
</tr>
<tr>
<td>G. HAMLET-like active molecule</td>
<td>Biosynthesis of nanoparticles (non-toxic to normal cells and tissues) act as a substitute of Alpha-lactalbumin in the liprotide (protein-lipid complex) where oleic acid plays the therapeutic role</td>
<td>[12]</td>
</tr>
<tr>
<td>H. HAMLET can be prepared from non-specific sources but renders same effects in therapeutic questions</td>
<td>Programmed cell death and cancer specific cytotoxicity have observed when Alpha-lactalbumin-oleic acid complex source is from bovine</td>
<td>[13,14]</td>
</tr>
</tbody>
</table>

Table 1: Analysis of different modes of activity of HAMLET against cancer cells.
Like apoptin, HAMLET meddles with chromatin structures proposing that particularly these cell structures are critical for its tumor-particular apoptosis acceptance [15]. HAMLET activatestes 20S proteasomes, which additionally adds to cell demise. HAMLET initiates tumor-specific apoptosis in a p53-free way. Over-articulation of the counter apoptotic Bcl-2 and caspase restraint does not save HAMLET positive cells. As of late, have given proof that HAMLET initiates macro-autophagy [16, 17].

<table>
<thead>
<tr>
<th>Clinical study on</th>
<th>Clinical outcome [16]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bladder cancer</td>
<td>8/9 patients showed tumor regression No adverse reactions were reported</td>
</tr>
<tr>
<td>Skin papilloma</td>
<td>29/5 patients with complete cure No side effect detected</td>
</tr>
</tbody>
</table>

Table 2: Main Therapeutic and mechanistic cell death aspects of HAMLET.

Macro-autophagy is a lysosomal catabolic pathway reusing cell particles. In malignancy cells, the macro-autophagy pathways have been changed in contrast with their ordinary partners (Høyer-Hansen and Jäättelä, 2008), which may clarify (to some degree) the watched tumor-specific action of HAMLET. Future ponders must be completed to recognize in detail the exact components empowering HAMLET’s tumor-particular apoptosis for all these tumor cells.

References
Advances in Pharmacology and Clinical Trials


